News

Those with metastatic castration-resistant prostate cancer in the BRCA subgroup experienced worse outcomes vs those in non-BRCA subgroups, according to the results of the CAPTURE trial.

A study found that treatment with HEPZATO KIT showed a promising response rate of 36.3% for patients with unresectable metastatic uveal melanoma.

If approved, this would mark the first Epstein-Barr virus-related mRNA therapeutic cancer vaccine.

Ariel Lopez-Chavez, MD, discusses ongoing research in the small cell lung cancer space.

Compared with ruxolitinib, momelotinib improved mild, moderate, and severe anemia in patients with myelofibrosis who were naive to JAK inhibitors, according to the phase 3 SIMPLIFY-1 study.

In an interview with Targeted Oncology, Shilpa Gupta, MD, discussed the rationale and potential significance of the MAIN-CAV trial in patients with locally advanced/metastatic urothelial carcinoma.

9MW2821 was granted an orphan drug designation from the FDA and is being evaluated for the potential treatment of esophageal cancer, as well as other cancers.

The phase 3 KEYNOTE-B21 study missed its primary end point, as pembrolizumab plus chemotherapy did not improve disease-free survival in newly diagnosed, high-risk endometrial cancer.

A phase 3 study evaluating uproleselan in relapsed/refractory acute myeloid leukemia missed its primary end point of overall survival.

As part of its Speaking Out video series, Targeted Oncology spoke with Howard D. Edington, MD, about the benefits of using oncolytic viruses in cancer treatment.

For World Ovarian Cancer Day, Eirwen M. Miller, MD, discussed the current state of ovarian cancer treatment, new developments in the space, and unmet needs.

Sanjay K. Juneja, MD, delves into what being recognized as an oncology icon for Targeted Oncology means to him.

With the clearance of an investigational new drug application for BTX-9341 from the FDA, a phase 1 trial will evaluate the agent in HR-positive/HER2-negative breast cancer.

In an interview with Targeted Oncology, Kayla Giannetti, MSN, APRN-CNP, discussed the background of the study, along with its findings and implications for community oncologists.

Early research suggests setanaxib combined with pembrolizumab may be a promising treatment for patients with squamous cell carcinoma of the head and neck.

The FDA has approved ColoSense, a stool screening test with 93% accuracy for colon cancer in average-risk adults over the age of 45. This noninvasive option may boost early detection rates.

If approved, zenocutuzumab would be the first targeted therapy for neuregulin 1 fusion-positive lung and pancreatic cancers.

The American Urological Association Annual Meeting took place May 3-6, 2024, in San Antonio, Texas, where data across the field of urologic oncology were presented.

Raajit K. Rampal, MD, PhD, discusses how the field of gene therapy and precision medicine is evolving in the context of myelofibrosis treatment.

Sima Porten, MD, MPH, discusses the rationale for the phase 3 SunRISe-5 study of TAR-200 in non-muscle invasive bladder cancer and unmet needs in this patient population.

A clinical trial to evaluate EIS-12656 in patients with specific types of advanced solid tumors will begin following the clearance of an investigational new drug application from the FDA.

The FDA is considering a subcutaneous nivolumab formulation for various solid tumors based on promising data from the phase 3 CheckMate -67T trial. A target action date has been set for December 29, 2024.

May 6, 2024, is Melanoma Monday. In this article, Niroshana Anandasabapathy, MD, PhD, explores how advancements in detection and treatment are improving the fight against melanoma.

Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.

Non-muscle invasive bladder cancer treatment with TAR-210 demonstrated safety and clinical activity in FGFR-altered high- and intermediate-risk patient groups.

In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.

Nadofaragene firadenovec maintained its durable clinical activity at 5 years in patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer.

Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.

Combination therapy with nivolumab and gemcitabine-cisplatin showed promising results in treating metastatic urothelial carcinoma with significantly improved overall survival and progression-free survival rates.

Combination nivolumab and nab-paclitaxel may be a safe and effective treatment for patients with muscle-invasive bladder cancer.